AbBC Therapies is a next generation ADC and immunotoxin company that utilizes a biological conjugation process to target and deliver Granzyme B to cells
To learn more, please contact:
Claire Thuning-Roberson, PhD, CEO; email: claireroberson@h2biologics.com, cell: 954-661-7555
Ian Estepan, Executive Chairman; email: iestepan@sarepta.com, cell: 617-460-9771